Skip to main content

Advertisement

SpringerLink
Log in

Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O’Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319–1331

    Article  CAS  Google Scholar 

  2. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O’Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ (2019) Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380(22):2104–2115

    Article  CAS  Google Scholar 

  3. Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 395(10218):132–141

    Article  CAS  Google Scholar 

  4. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754–766

    Article  CAS  Google Scholar 

  5. Johnsrud AJ, Johnsrud JJ, Susanibar SA, Kamimoto JJ, Kothari A, Burgess M, van Rhee F, Rico JC (2019) Infectious and immunological sequelae of daratumumab in multiple myeloma. Br J Haematol 185(1):187–189

    Article  Google Scholar 

  6. Casneuf T, Adams HC III, van de Donk N et al (2021) Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. 35(2):573–584

    Article  CAS  Google Scholar 

  7. Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, Ghoda L, Gunes EG, Sanchez JF, Khalife J, Martella M, Karanes C, Htut M, Wang X, Rosenzweig M, Chowdhury A, Sborov D, Miles RR, Yazaki PJ, Ebner T, Hofmeister CC, Forman SJ, Rosen ST, Marcucci G, Shively J, Keats JJ, Krishnan A, Pichiorri F (2021) Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia. 35(1):189–200

    Article  CAS  Google Scholar 

  8. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NWCJ, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 128(3):384–394

    Article  CAS  Google Scholar 

  9. Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, Ljungman P, Wagner AK, Alici E (2019) Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PLoS One 14(2):e0211927

    Article  CAS  Google Scholar 

  10. McCullough KB, Hobbs MA, Abeykoon JP, Kapoor P (2018) Common adverse effects of novel therapies for multiple myeloma (MM) and their management strategies. Curr Hematol Malig Rep 13(2):114–124

    Article  Google Scholar 

  11. Delforge M, Ludwig H (2017) How I manage the toxicities of myeloma drugs. Blood. 129(17):2359–2367

    Article  CAS  Google Scholar 

  12. Lavi N, Okasha D, Sabo E, Oren I, Benyamini N, Bar-Yoseph H (2018) Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma. Eur J Haematol 101(5):699–702

    Article  Google Scholar 

  13. Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk N (2019) Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment. Clin Lymphoma Myeloma Leuk 19(1):e9–e11

    Article  Google Scholar 

  14. Nakagawa R, Onishi Y, Kawajiri A, Onodera K, Furukawa E, Sano S, Saito K, Ichikawa S, Fujiwara T, Fukuhara N, Harigae H (2019) Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. Ann Hematol 98(8):1999–2001

    Article  Google Scholar 

Download references

Acknowledgements

We thank Enago (www.enago.jp/) for their English language editing services.

Author information

Authors and Affiliations

  1. Department of Hematology, National Cancer Center Hospital East, 6-5-1, Kashiwano-ha, Kashiwa, Chiba, 277-8577, Japan

    Rikako Tabata, Nobuhiko Yamauchi, Yong-Mei Guo, Hirotaka Nakamura, Akihito Nagata, Chi Song-Gi, Yosuke Minami & Junichiro Yuda

  2. Department of Pharmacy, National Cancer Center Hospital East, Chiba, Japan

    Nobue Sato

Authors
  1. Rikako Tabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobue Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nobuhiko Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong-Mei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hirotaka Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akihito Nagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chi Song-Gi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yosuke Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Junichiro Yuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Junichiro Yuda.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tabata, R., Sato, N., Yamauchi, N. et al. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens. Ann Hematol 101, 465–467 (2022). https://doi.org/10.1007/s00277-021-04525-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04525-9

Search

Navigation